No abstract

Epidermal growth factor (EGF) and transforming growth factor alpha (TGF-alpha) are ligands for the EGF-receptor and act as mitogens for a variety of tissues. TGF-alpha, in particular, has been implicated as an autocrine growth factor for several cancer cell lines. Over the last 10 years many groups have examined the structure-function relationships in EGF/TGF-alpha in attempts to develop antagonists or agonists. In this review the results of these studies are summarised and related to the three-dimensional structure of EGF/TGF-alpha. The difficulties associated with the purification and characterisation of analogues of EGF/TGF-alpha and with the biological assays are discussed. It is clear that these difficulties have, in some cases, led to apparently contradicting results. The available binding data indicate that the receptor interaction surface for EGF/TGF-alpha might encompass one complete side of the molecule with a few strong binding determinants, in particular Arg41 and Leu47. The arginine at position 41 is the most critical residue and its full hydrogen-bonding capacity is needed for strong binding of EGF/TGF-alpha to the EGF-receptor. As this side of the molecule consists of residues from both the N- and C-terminal domain, it seems unlikely that agonists or antagonists can be developed on the basis of short peptides taken from the primary sequence. This concept is supported by the available binding and activity data.

No abstract

Dynamic 'H NMR measurements of the tetramethyl ether of p-tert-butylcalix[4]arene (2) show for the first time that all four possible conformations of one particular calix[4]arene are present, including the 1 ,balternate conformation. The thermodynamically most stable partial cone conformation readily interconverts to a cone or to a 1,3-alternate conformation; the interconversion to a 1,2-alternate conformation is much slower. The 1,2-alternate conformation of 2 is the kinetically stable conformation at the I H NMR time scale. The 1,a-alternate conformation was confirmed by comparison of its 'H NMR spectrum with that of the newly synthesized tetraethyl ether of p-tert-butylcalix[4]arene in a fixed 1,2-alternate conformation (6), of which the X-ray structure was determined. Partial rigidification of the calix[4]arene moiety in four different ways was achieved by replacing two of the methoxy groups of the tetramethyl ether 2 by ethoxy groups. The relative thermodynamic stabilities of the conformations of the calix[4]arene are influenced strongly by this relatively small change; in particular the 1,2-alternate conformation becomes much more stable. For the anti-1,3-diethyl-2,4-dimethyl ether 7b the 1,2-alternate is even the thermodynamically most stable conformation. Molecular mechanics calculations indicate that this is caused by the combined favorable effects on the electrostatic energy of the inside orientation of the methoxy groups and the relative large distance between the two ethoxy groups. The tetraethyl ether of p-tert-butylcalix[4]arene is not flexible at room temperature, but it equilibrates in solution at temperatures above 100 "C to a mixture of also all the four possible conformations.

The mAb A33 detects a membrane antigen that is expressed in normal human colonic and small bowel epithelium and >95% of human colon cancers. It is absent from most other human tissues and tumor types. The murine A33 mAb has been shown to target colon cancer in clinical trials, and the therapeutic potential of a humanized antibody is currently being evaluated. Using detergent extracts of the human colon carcinoma cell lines LIM1215 and SW1222, in which the antigen is highly expressed, the molecule was purified, yielding a 43-kDa protein. The N-terminal sequence was determined and further internal peptide sequence obtained following enzymatic cleavage. Degenerate primers were used in PCRs to produce a probe to screen a LIM1215 cDNA library, yielding clones that enabled us to deduce the complete amino acid sequence of the A33 antigen and express the protein. The available data bases have been searched and reveal no overall sequence similarities with known proteins. Based on a hydrophilicity plot, the A33 protein has three distinct structural domains: an extracellular region of 213 amino acids (which, by sequence alignment of conserved residues, contains two putative immunoglobulin-like domains), a single hydrophobic transmembrane domain, and a highly polar intracellular tail containing four consecutive cysteine residues. These data indicate that the A33 antigen is a novel cell surface receptor or cell adhesion molecule in the immunoglobulin superfamily.